deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01104259

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Estrogen Receptor-negative Breast Cancer HER2-negative Breast Cancer Hereditary Breast/Ovarian Cancer - BRCA1 Hereditary Breast/Ovarian Cancer - BRCA2 Male Breast Cancer Progesterone Receptor-negative Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer Triple-negative Breast Cancer
Interventions cisplatin laboratory biomarker analysis pharmacological study veliparib vinorelbine tartrate
Updated 8 times since 2017 Last updated: Aug 8, 2017 Started: Jul 31, 2010 Primary completion: Feb 28, 2015 Completion: Apr 30, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Estrogen Receptor-negative Breast Cancer and HER2-negative Breast Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 8 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshotActive Not Recruiting~Mar 2017 – ~Aug 2017 · 5 months · monthly snapshotActive Not Recruiting~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Aug 2017 — Jun 2018 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

  1. Mar 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE1

  2. Feb 2017 — Mar 2017 [monthly]

    Active Not Recruiting PHASE1

  3. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • University of Washington
Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations